Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT05954910
Active, not recruiting Observational

A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

NCT05954910 · tracked via the Priya Life Science China tracker
Sponsor
Hoffmann-La Roche
Phase
Observational
Started
2023-08-25
Last updated
2026-10-30

Condition(s) studied

Diffuse Large B-Cell Lymphoma

Investigational drug(s) / intervention(s)

Polatuzumab Vedotin →

Polatuzumab Vedotin: Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.

Study summary

The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Be diagnosed as DLBCL * Cohort 1: diagnosed as unfit/frail DLBCL. The unfit/frail is defined as aged 80 years or older, or younger than 80 years but with comorbidity and not tolerant to the standardized dose of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy according to investigator's judgment * Cohort 2: diagnosis as DLBCL but could not be classified into unfit/frail * Cohort 3: relapse or refractory to previous treatment Exclusion Criteria: * Participant who currently participates in or with plan to participate in any interventional clinical trial * Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Primary outcome measure(s)

  • Cohorts 1 and 2: Progression Free Survival at 24 months (PFS24) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma — At 24 months
  • Cohort 3: PFS Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma — Baseline up to end of study (EOS) (approximately 38 months)

Trial sites (29)

FacilityCityRegionStatus
Peking Union Medical College Hospital Beijing China
Peking University Third Hospital Beijing China
Beijing Hospital of Ministry of Health Beijing China
Beijing Tongren Hospital, Capital Medical University Beijing China
The First Bethune Hospital of Jilin University Changchun China
Xiangya Hospital of Centre-South University Changsha China
Third Xiangya Hospital of Central South University Changsha China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital Chengdu China
Zhujiang Hospital, Southern Medical University Guangzhou China
Guizhou Cancer Hospital Guiyang China
Hainan Cancer Hospital Haikou China
Affiliated Hospital of Inner Mongolia Medical University Hohhot China
Jiangxi Cancer Hospital Nanchang China
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University) Nanjing China
Jiangsu Cancer Hospital Nanjing China
The Affiliated Hospital Of Qingdao University Qingdao China
Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China
Tongji Hospital of Tongji University Shanghai China
China Medical University (CMU) First Affiliated Hospital Shenyang China
The Fourth Hospital of Hebei Medical University Shijiazhuang China
Shanxi Province Cancer Hospital Taiyuan China
Tianjin Medical University General Hospital Tianjin China
Tianjin Cancer Hospital Tianjin China
Xinjiang Medical University Cancer Hospital Ürümqi China
Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
Wuxi People's Hospital Wuxi China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University Xi'an China
The Affiliated Hospital of Xuzhou Medical University Xuzhou China
Henan Cancer Hospital Zhengzhou China

More Hoffmann-La Roche trials in China

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma Recruiting
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy Active, not recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Recruiting
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease Recruiting
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer Active, not recruiting

Other trials for the same condition

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting soon
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma Recruiting
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research Recruiting
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) Active, not recruiting
CHiR Therapy for Elderly DLBCL Intolerant to Chemo Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05954910 on ClinicalTrials.gov ↗ ← All trials in China